


IN THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-13 (Cancelled).

14. (Previously Presented) A compound of general formula [I]:



wherein:

R¹ and R² are each independently selected from the group consisting of:

- (1) optionally hydroxyl- or halogen-substituted lower alkyl,
- (2) optionally R⁹-substituted 3 to 6-membered cycloalkyl, and
- (3) optionally R⁹-substituted 4 to 6-membered heterocycloalkyl, or
- (4) R¹ and R² together form a 4 to 11-membered crosslinking, non-crosslinking or spiro ring aliphatic nitrogen-containing heterocycle, with the nitrogen atom to which they bind, one or two optional hydrogen atoms in the aliphatic nitrogen-containing heterocycle being optionally substituted with R⁹;

R³, R⁴, R⁶ and R⁷ are each independently selected from the group consisting of:

- (1) hydrogen,
- (2) hydroxyl,
- (3) halogen, and
- (4) optionally halogen-substituted lower alkyl;

R⁵ stands for:

- (1) hydrogen, or
- (2) optionally halogen-substituted lower alkyl;

each R⁸ is independently selected from the group consisting of:


- (1) halogen,
- (2) lower alkyl, and
- (3) lower alkyloxy;

R⁹ is selected from the group consisting of hydroxyl, amino, mono-lower alkylamino, di-lower alkylamino, optionally hydroxyl- or halogen-substituted lower alkyl, (lower alkyloxy carbonyl)amino, lower alkyloxy carbonyl- (lower alkyl)amino, lower

alkylcarbonylamino, lower alkylcarbonyl(lower alkyl)amino, mono-lower alkylcarbamoyl-lower alkyl)amino, di-lower alkylcarbamoyl(lower alkyl)amino, lower alkylsulfonylamino, lower alkylsulfonyl(lower alkyl)amino, oxo and 2-oxopyrrolidinyl; and
n is 0, 1, 2, 3 or 4;
or a pharmaceutically acceptable salt thereof.

15. (Previously Presented) The compound according to Claim 14, wherein: R¹ is lower alkyl, and R² is selected from the group consisting of optionally hydroxyl-substituted lower alkyl, tetrahydrofuranyl and optionally R⁹-substituted pyrrolidinyl, or a pharmaceutically acceptable salt thereof.


16. (Previously Presented) The compound according to Claim 14, wherein: the 4 to 11-membered crosslinking, non-crosslinking or spiro ring aliphatic nitrogen-containing heterocycle formed by R¹ and R² together with the nitrogen atom to which they bind is represented by a formula (A):



wherein R^a is R⁹ or two R^a's together form -(CH₂)_x-(NH)-(CH₂)_y-, hydrogen in the substituent group may optionally be substituted with lower alkyl, lower alkylcarbonyl or oxo, x and y are each independently selected from 0, 1, 2, 3 or 4, provided that 3 ≤ x + y ≤ 4, and m is selected from 0, 1 or 2; or a pharmaceutically acceptable salt thereof.

17. (Previously Presented) The compound according to Claim 16, wherein: R^a is selected from the group consisting of lower alkylcarbonyl(lower alkyl)amino, lower alkylsulfonyl(lower alkyl)amino, lower alkyloxycarbonyl(lower alkyl)amino, and di-lower alkylcarbamoyl(lower alkyl)amino, and
m=1;
or a pharmaceutically acceptable salt thereof.

18. (Previously Presented) The compound according to Claim 16, wherein: m=2, and the two R^a's together form a group selected from the group consisting of:



wherein: R¹⁰ is selected from lower alkyl and lower alkylcarbonyl; or a pharmaceutically acceptable salt thereof.

19. (Previously Presented) The compound according to Claim 16, wherein: the aliphatic nitrogen-containing heterocycle represented by the formula (A) is selected from the group consisting of:

1-methyl-2-oxo-1,7-diazaspiro[4.4]nonan-7-yl, 7-methyl-8-oxo-2,7-diazaspiro[4.4]nonan-2-yl, 3-[acetyl(methyl)amino]pyrrolidin-1-yl, 3-[propionyl(methyl)amino]pyrrolidin-1-yl, 3-[isobutyryl(methyl)-amino]pyrrolidin-1-yl, 3-[methanesulfonyl(methyl)amino]pyrrolidin-1-yl, 3-[methoxycarbonyl(methyl) amino]pyrrolidin-1-yl, 3-{{(dimethylamino)carbonyl}(methyl)amino}pyrrolidin-1-yl, 6-acetyldecahydro-pyrrolo[3,4-d]azepin-2-yl, and 2-oxo[1.3']bipyrrolidinyl-1'-yl; or a pharmaceutically acceptable salt thereof.

20. (Previously Presented) The compound according to Claim 14, wherein: R⁸ is a fluorine atom or a methoxy group, or a pharmaceutically acceptable salt thereof.

21. (Previously Presented) The compound according to Claim 14, wherein: selected from the group consisting of:

- (1) 5-(4-fluorophenyl)-N-[2-(1-methyl-2-oxo-1,7-diazaspiro[4,4]nonan-7-yl)-6-quinolinyl]-2-pyrimidinecarboxamide,
- (2) 5-(4-fluorophenyl)-N-[2-(7-methyl-8-oxo-2,7-diazaspiro[4,4]-nonan-2-yl)-6-quinolinyl]-2-pyrimidinecarboxamide,
- (3) N-(2-[(3R)-3-[isobutyryl(methyl)amino]-1-pyrrolidinyl]-6- quinolinyl)-5-phenyl-2-pyrimidine carboxamide,
- (4) N-[2-(6-acetyldecahydropyrrolo[3,4-d]azepin-2-yl)-6- quinolinyl]-5-phenyl-2-pyrimidine carboxamide,
- (5) N-[2-[(3R)-3-[acetyl(methyl)amino]-1-pyrrolidinyl]-6-quinolinyl]-5-phenyl-2-pyrimidine carboxamide,

- (6) 5-phenyl-N-(2-[(3R)-3-[propionyl(methyl)amino]-1- pyrrolidinyl]-6-quinoliny)-2-pyrimidine carboxamide,
- (7) N-(2-[(3R)-3-[methanesulfonyl(methyl)amino]-1-pyrrolidinyl]-6-quinoliny)-5-phenyl-2-pyrimidinecarboxamide,
- (8) N-(2-[(3R)-3-[methoxycarbonyl(methyl)amino-1- pyrrolidinyl]-6-quinoliny)-5-phenyl-2-pyrimidinecarboxamide,
- (9) N-(2-[(3R)-3-[(dimethylamino)carbonyl](methyl)amino]-1-pyrrolidinyl]-6-quinoliny)-5-phenyl-2-pyrimidinecarboxamide,
- (10) N-(2-[isopropyl(methyl)amino]-6-quinoliny)-5-phenyl-2-pyrimidinecarboxamide,
- (11) 5-(4-fluorophenyl)-N-(2-[(3R)-3-[isobutyryl(methyl)amino]-1-pyrrolidinyl]-6-quinoliny)-2-pyrimidinecarboxamide,
- (12) N-(2-[(3R)-3-[acetyl(methyl)amino]-1-pyrrolidinyl]-6-quinoliny)-5-(4-fluorophenyl)-2-pyrimidine carboxamide,
- (13) 5-(4-fluorophenyl)-N-(2-[methyl(tetrahydro-3-furanyl)amino]-6-quinoliny)-2-pyrimidine carboxamide and
- (14) 5-(3-fluorophenyl)-N-(2-[(3R)-3-[isobutyryl(methyl)amino]-1-pyrrolidinyl]-6-quinoliny)-2-pyrimidine carboxamide,

or a pharmaceutically acceptable salt thereof.


Claims 22-24 (Cancelled).

25. (Previously Presented) A method for treating obesity in a human subject in need of such treatment comprising administering to the human subject of a therapeutically effective amount of a compound according to Claim 14, or a pharmaceutically acceptable salt thereof.


26. (Previously Presented) A pharmaceutical composition comprising a compound according to Claim 14, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

27. (Previously Presented) A process for preparing the compound of general formula [I] of Claim 14, wherein: $R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8$ and n have the same significations as given in Claim 14,

which comprises the step of subjecting a compound of a general formula [II]:



wherein R¹, R², R³, R⁴ and R⁵ are as defined in Claim 14;
and a compound of a general formula [III]



wherein R⁶, R⁷, R⁸ and n are as defined in Claim 14;
to an amidation reaction.